Nature and science of sleep · 2026
The Clinical, Humanistic, and Economic Burden of Idiopathic Hypersomnia in the United States: Analysis of the National Health and Wellness Survey.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Drachenberg Caroleen, Cambron-Mellott M Janelle, Yang Lin, Balkaran Bridget L, Whalen Marisa, Plante David T
Аннотация
PURPOSE: Limited self-reported data on the real-world burden of idiopathic hypersomnia exist from a representative sample of the US general adult population. This study described the clinical, humanistic, and economic burden of adults with idiopathic hypersomnia compared to matched adults without idiopathic hypersomnia.
PATIENTS AND METHODS: This cross-sectional study used 2021 and 2023 US National Health and Wellness Survey data. Propensity score matching (1:2) was performed for adults (≥18 years) who self-reported a physician diagnosis of idiopathic hypersomnia and adults without idiopathic hypersomnia (non-idiopathic hypersomnia cohort). Post matching, outcomes were compared between cohorts using cluster-robust regression models; P values for primary outcomes were not adjusted for multiplicity.
RESULTS: Included were 163 adults with idiopathic hypersomnia (64.4% female, mean age 38.45 years) and 326 matched adults without idiopathic hypersomnia (66.0% female, mean age 39.60 years). The idiopathic hypersomnia cohort had higher prevalence of comorbidities (eg cardiovascular, cardiometabolic, sleep, psychiatric), higher mean Charlson comorbidity index scores (1.43 vs 0.34), and reported worse depression (PHQ-9) and anxiety (GAD-7) and poorer mental health, physical function (SF-36v2, RAND-36), and HRQoL (EQ-5D-5L, SF-6D, EQ-VAS) compared to the matched non-idiopathic hypersomnia cohort (P < 0.01). The idiopathic hypersomnia cohort reported more mean healthcare provider visits (13.34 vs 3.14), emergency department visits (0.88 vs 0.45), and hospitalizations (0.95 vs 0.35) in the past 6 months and higher annualized direct medical costs ($46,424.39 vs $14,700.21) than the matched non-idiopathic hypersomnia cohort (P < 0.05). The idiopathic hypersomnia cohort reported greater mean work productivity loss (49.07 vs 32.28) and activity impairment (48.22 vs 30.77), and annualized indirect costs ($15,269.22 vs $10,576.96) than the matched non-idiopathic hypersomnia cohort (P < 0.05).
CONCLUSION: This study highlights the substantial real-world burden, including comorbidity, HRQoL, and economic, of idiopathic hypersomnia compared to the matched non-idiopathic hypersomnia cohort.
PATIENTS AND METHODS: This cross-sectional study used 2021 and 2023 US National Health and Wellness Survey data. Propensity score matching (1:2) was performed for adults (≥18 years) who self-reported a physician diagnosis of idiopathic hypersomnia and adults without idiopathic hypersomnia (non-idiopathic hypersomnia cohort). Post matching, outcomes were compared between cohorts using cluster-robust regression models; P values for primary outcomes were not adjusted for multiplicity.
RESULTS: Included were 163 adults with idiopathic hypersomnia (64.4% female, mean age 38.45 years) and 326 matched adults without idiopathic hypersomnia (66.0% female, mean age 39.60 years). The idiopathic hypersomnia cohort had higher prevalence of comorbidities (eg cardiovascular, cardiometabolic, sleep, psychiatric), higher mean Charlson comorbidity index scores (1.43 vs 0.34), and reported worse depression (PHQ-9) and anxiety (GAD-7) and poorer mental health, physical function (SF-36v2, RAND-36), and HRQoL (EQ-5D-5L, SF-6D, EQ-VAS) compared to the matched non-idiopathic hypersomnia cohort (P < 0.01). The idiopathic hypersomnia cohort reported more mean healthcare provider visits (13.34 vs 3.14), emergency department visits (0.88 vs 0.45), and hospitalizations (0.95 vs 0.35) in the past 6 months and higher annualized direct medical costs ($46,424.39 vs $14,700.21) than the matched non-idiopathic hypersomnia cohort (P < 0.05). The idiopathic hypersomnia cohort reported greater mean work productivity loss (49.07 vs 32.28) and activity impairment (48.22 vs 30.77), and annualized indirect costs ($15,269.22 vs $10,576.96) than the matched non-idiopathic hypersomnia cohort (P < 0.05).
CONCLUSION: This study highlights the substantial real-world burden, including comorbidity, HRQoL, and economic, of idiopathic hypersomnia compared to the matched non-idiopathic hypersomnia cohort.